Novel gene targeting therapies, protein disruptors and why ANP's recent trial success have investors buzzing - a podcast by Stockhead

from 2020-02-05T15:01

:: ::

Tim speaks with Antisense (ASX:ANP) managing director and CEO, Mark Diamond

Further episodes of The Health Kick Podcast with Tim Boreham

Further podcasts by Stockhead

Website of Stockhead